v3.25.2
SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA
NOTE 9:-
SEGMENTS, GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA
 
The following table presents selected financial information with respect to the Company’s single operating segment and includes information about segment revenues and significant segment expenses, for the six months ended June 30, 2025 and 2024:
 
   
Six months ended
June 30,
  
   
2025
    
2024
  
   
Unaudited
  
   
$
    
$
  
Total Revenues
    
3,541
      
9,261
  
                 
Less:
                
          R&D expenses
                
               Preclinical
    
6,659
      
8,546
  
               Clinical
    
6,982
      
7,107
  
           SG&A
    
4,851
      
4,592
  
           Financial income, net
    
(2,314
)
    
(2,528
)
           Taxes on income
    
14
      
14
  
           Other segment expenses*
    
1,872
      
920
  
                 
Net loss
    
(14,523
)
    
(9,390
)
 
*Other segment expense (income) during the six months ended June 30, 2025 and 2024 includes property and equipment depreciation, GS-0321 asset of set-up activities, share-based compensation and other adjustments.
 
Operations in Israel include research and development, clinical operations, general and administrative, marketing and business development, and operations in the United States include clinical operations. Total revenues are attributed to geographic areas based on the location of the end customer.
 
The following represents the total revenue for the six-month periods ended June 30, 2025 and 2024 by region based on the invoicing address of customers:
 
   
Six months ended
June 30,
  
   
2025
    
2024
  
   
Unaudited
  
Revenue from sales to customers:
            
             
United States
  
$
3,541
    
$
4,261
  
Europe
    
-
      
5,000
  
                 
Total revenues
  
$
3,541
    
$
9,261
  

 

Contract Balances
 
Of the $43,677 and $36,541 of the deferred revenue recorded as of December 31, 2024 and 2023, respectively, the Company recognized $3,541 and $4,261 as revenue during the six months periods ended June 30, 2025 and 2024, respectively.
 
Remaining Performance Obligation
 
The Company’s remaining performance obligations are comprised of revenue not yet recognized. As of June 30, 2025, the aggregate amount of the transaction price allocated to remaining performance obligations was $40,137 that the Company expects to recognize as revenue. As of June 30, 2025, the Company expects to recognize 26% of its remaining performance obligations as revenue over the next 12 months.